Document Detail


Investigation of differentially expressed proteins due to the inhibitory effects of berberine in human liver cancer cell line HepG2.
MedLine Citation:
PMID:  16880943     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The investigation of differentially expressed proteins was used together with other techniques to study the inhibitory effects of two different doses of berberine in human liver cancer cell line HepG2. For HepG2 cells treated with 24.0 mg l(-1) of berberine, an increase in the sub G(0) phase that was indicative of cell death was observed in cell cycle analysis with flow cytometry. However, no significant increase in sub G(0) was observed in HepG2 cells treated with 4.0 mg l(-1) of berberine. Using flow cytometric analysis, significant activation of caspase 3 was not observed with HepG2 cells treated with 4.0 and 24.0 mg l(-1) of berberine. In this work, labeling of cells with stable isotope was not used in the proposed method developed. The whole cell lysates from the control and treated cells were digested with trypsin and the peptides were separated by two-dimensional (cation exchange and reversed phase) liquid chromatography and tandem mass spectrometry. Our preliminary data showed that the proposed platform provided a rapid approach to study the molecular mechanism due to the inhibitory effects of different doses of the berberine on HepG2 cell lines. This included a network of proteins involved in mitogen-activated protein kinase (MAPK) phosphorelay systems, metabolism, regulation of cell cycle and DNA damage response. The differentially expressed proteins identified using the current approach were consistent with the data obtained from cell cycle analysis with flow cytometry.
Authors:
Yan Lin Tan; David Goh; Eng Shi Ong
Related Documents :
8082723 - Isolation of a mammalian cell cycle ts mutant, tsjt663, defective in preparation for pa...
7452103 - Transition phenomena in bacterial growth between logarithmic and stationary phases.
22503103 - A redox-regulated sumo/acetylation switch of hipk2 controls the survival threshold to o...
Publication Detail:
Type:  Journal Article     Date:  2006-03-30
Journal Detail:
Title:  Molecular bioSystems     Volume:  2     ISSN:  1742-206X     ISO Abbreviation:  Mol Biosyst     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-08-01     Completed Date:  2006-10-25     Revised Date:  2007-06-12    
Medline Journal Info:
Nlm Unique ID:  101251620     Medline TA:  Mol Biosyst     Country:  England    
Other Details:
Languages:  eng     Pagination:  250-8     Citation Subset:  IM    
Affiliation:
Applied Science School, Temasek Polytechnic, Singapore, Republic of Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Berberine / pharmacology*,  therapeutic use
Cell Cycle / drug effects
Chromatography, High Pressure Liquid / methods
Humans
Inhibitory Concentration 50
Liver Neoplasms / drug therapy
Mass Spectrometry / methods
Proteome / drug effects*
Proteomics / methods
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Proteome; 2086-83-1/Berberine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Prelim...
Next Document:  The impact of systems biology and biosimulation on drug discovery and development.